keine Finanzberatung

LH · Labcorp

Clinical labs plus drug-development services

Risiko 3/10 · LOW-MODERATE RISK · diagnostics duopolist · $326.89 ▼ 1.39%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $326.89
  • Market cap $26.5B
  • P/E (ttm) 27.04
  • Div yield 0.88%
  • 52-wk range $244.52 – $341.80
  • Index rank #366 / —

Wichtigste Risiken

  • Reimbursement and payer pressure on test pricing (Shareholders) — MED
  • Debt-funded lab acquisition strategy (Bondholders) — MED
  • Valuation rich versus its own growth history (Shareholders) — MED
  • Competition in high-margin oncology diagnostics (Shareholders) — LOW

Fazit

High-quality defensive at a full price — the business earns its multiple only if the oncology bet keeps delivering.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.